Kratom’s Promise and Peril: Inside a Controversial Herbal Remedy

Walk into a gas station, vape shop, or health food store in many parts of the United States and chances are you will find products labeled “contains kratom,” from neon-colored shots to powdered capsules and loose leaf teas. Native to Southeast Asia, kratom (Mitragyna speciosa) has been used for generations by farmers and laborers who chewed fresh leaves or brewed them into tea to sustain energy, lift mood, and manage pain during long days of physical work, a pattern of traditional use that is now well documented in ethnobotanical and pharmacology research from the region.

In recent years, this centuries-old tree has become the focus of a very modern debate: Is kratom a lifesaving plant-based tool that can ease chronic pain and help people manage opioid withdrawal, or an unregulated substance that carries its own risk of dependence and health harms? The answer, experts say, lies somewhere in between, and the complexities are evident in growing scientific interest, rising consumer demand, and an uneasy regulatory landscape that has yet to catch up with the speed of kratom’s spread.

Proponents frequently describe kratom as a “natural alternative” to prescription painkillers or mood medications, and online forums are crowded with first-person accounts of people who say the plant helped them cut back on opioids, ease anxiety, or function through lingering pain. The U.S. National Institute on Drug Abuse notes that many people report using kratom to alleviate drug withdrawal symptoms and cravings, particularly for opioids, and to address pain and mental health concerns, even as federal agencies stress that no kratom products are approved as medicines and that much remains unknown about long-term safety and optimal dosing.

The appeal is understandable in a country still grappling with a protracted opioid crisis and gaps in access to comprehensive pain and addiction care. For some, kratom appears to offer a measure of autonomy: an over-the-counter, plant-based substance that can be tailored to individual needs, whether that means a small dose to boost alertness and mood, or a higher dose for more pronounced analgesic and sedative effects. Researchers have found that kratom’s primary alkaloid, mitragynine, interacts with some of the same opioid receptors in the brain targeted by prescription pain medications, but in a pharmacologically distinct way that may blunt some risks associated with traditional opioids while introducing a profile of its own.

In surveys of kratom consumers in the United States, a majority report using the substance for self-managed pain, anxiety, or mood symptoms, and many say it has helped them reduce or discontinue other drugs, including opioids and alcohol. One large online survey of people who used kratom for pain relief found that more than 90 percent of respondents rated it as “very effective” for their condition, echoing themes heard by clinicians like therapist and addiction specialist Jana Wu, who has written about clients using kratom to navigate complicated recoveries from opioid use disorder and other substance problems.

Public health agencies, however, emphasize that individual success stories do not replace the need for systematic evidence and careful oversight. The U.S. Food and Drug Administration states plainly that kratom is not lawfully marketed as a drug, dietary supplement, or food additive in the United States and has warned consumers not to use kratom products because of the risk of serious adverse events, including liver toxicity, seizures, and the potential development of a substance use disorder; the agency’s dedicated information page on “FDA and Kratom” underscores that there are currently no approved medical uses for kratom and that many products are sold without quality controls.

Despite these warnings, kratom remains widely accessible in many states, where it may be sold in smoke shops, convenience stores, and online with few guardrails on age limits, labeling accuracy, or product purity. In the absence of federal regulation, some state legislatures have turned to so-called Kratom Consumer Protection Acts that seek to restrict sales to minors, require basic labeling standards, and limit certain forms of adulteration while preserving adult access. Florida, for example, recently enacted a law prohibiting kratom sales to anyone under 21 and defining kratom products in state statute, a model that advocates say could offer a pragmatic framework between outright bans and an unregulated marketplace.

On the research front, interest in kratom has accelerated as clinicians and scientists work to understand where the plant may fit in a broader toolbox of pain and addiction treatments. The National Institute on Drug Abuse describes a portfolio of ongoing studies examining kratom’s pharmacology, its potential as a treatment for chronic pain and opioid withdrawal, and real-world patterns of use in the United States, including an ecological momentary assessment study that tracks how people use kratom throughout their daily lives; these efforts, highlighted on NIDA’s dedicated “Kratom” resource page, aim to inform policy and clinical guidance with data rather than anecdotes alone.

Early clinical and laboratory work suggests that kratom’s primary compounds may act as so-called “atypical” opioids, producing analgesia and some euphoria while potentially limiting respiratory depression, a key driver of fatal overdose with traditional opioids. Some preclinical studies and small observational reports have hinted at lower overdose risk when kratom is used alone, and at the possibility that kratom-derived molecules could be developed into new medications that retain pain-relieving benefits without the same propensity for life-threatening breathing suppression, but scientists caution that translating these findings into real-world practice will require much more rigorous testing.

For individuals living with chronic pain or lingering post-acute withdrawal symptoms, the potential benefits can feel immediate and tangible. People who use kratom regularly often describe improved ability to work, care for families, and participate in daily life without the heavy sedation or cognitive blunting they experienced on some prescription opioids or sedatives. Others report that kratom tea or capsules help ease the emotional volatility that can accompany early recovery from opioids or alcohol, giving them a sense of stability while they engage in counseling, support groups, and other evidence-based treatments.

Still, clinicians who specialize in addiction medicine see another side of the story: patients who begin taking kratom to ease opioid cravings or manage pain and gradually find themselves escalating doses, organizing their days around kratom use, and experiencing withdrawal symptoms when they attempt to stop. In counseling settings, therapists like Wu describe clients whose growing dependence on kratom strained family relationships, drained bank accounts, and interfered with work in ways that felt eerily similar to their former opioid use, even if the immediate health risks appeared different.

The FDA and the federal Centers for Disease Control and Prevention have documented rare but serious outcomes linked to kratom, including liver injury, seizures, and, in some cases, deaths where kratom was one of multiple substances detected; a review of kratom-related safety issues published in the National Library of Medicine’s open-access database has stressed that adulterated products, high-dose extracts, and co-use with other drugs may amplify risks, particularly in people with underlying health conditions. At higher doses, kratom has been associated with symptoms such as nausea, constipation, rapid heart rate, elevated blood pressure, and, in susceptible individuals, hallucinations or psychosis-like experiences, especially when combined with other psychoactive medications.

When heavy or long-term users stop kratom abruptly, they may experience a withdrawal syndrome that, while generally less dangerous than withdrawal from alcohol or benzodiazepines, can be profoundly uncomfortable. Reports describe anxiety, irritability, muscle aches, insomnia, and depressed mood, along with cravings that can drive people back to use in the absence of structured support. Addiction specialists say that for individuals with a history of opioid use disorder, this cycle can feel familiar, and they recommend approaching kratom changes with the same planning and medical oversight applied to other substance use.

For people who feel that kratom use has become problematic, treatment options mirror those used for other substance use disorders, beginning with a safe, supported detoxification process. Medical detox programs, including those described in resources such as the medical detox overview from Psychology Today, can help manage acute withdrawal symptoms such as body aches, chills, and nausea, while ensuring that any co-occurring conditions or medications are taken into account and that complications are swiftly addressed.

Beyond the initial detox phase, ongoing care often includes a combination of individual therapy, group counseling, and family sessions aimed at exploring why kratom use escalated and what needs it was meeting. Cognitive-behavioral approaches, trauma-informed therapy, and relapse prevention training can help people develop alternative coping strategies for stress, loss, or mental health challenges that may have driven self-medication with kratom in the first place. Peer support groups—including newer, exploratory meetings focused specifically on kratom use—offer a space to discuss practical questions such as distinguishing use from misuse, navigating long-term effects, and rebuilding relationships affected by substance use.

Some people who began using kratom to self-treat opioid use disorder later decide, in consultation with clinicians, to transition to established, FDA-approved medications such as buprenorphine or methadone that have been extensively studied and are recommended in federal guidelines; information from the U.S. Substance Abuse and Mental Health Services Administration’s medications for substance use disorders resource explains how these treatments can reduce overdose risk and support long-term recovery when combined with counseling and supportive services.

For those who continue to use kratom as part of a broader wellness strategy, experts emphasize the importance of informed consent and harm reduction. That means understanding that kratom is not a benign herbal tea, that product quality can vary widely, and that combining kratom with alcohol, sedatives, or other opioids may increase the likelihood of adverse events. It also means paying attention to dose, frequency, and emerging side effects, and being willing to reassess use if signs of dependence or health problems appear, rather than assuming that “natural” automatically equals “safe.”

Holistic practices such as mindfulness, meditation, yoga, and physical therapy can play a complementary role, helping people cultivate self-awareness and self-compassion while they experiment with different ways of managing pain or cravings. The U.S. National Center for Complementary and Integrative Health provides evidence-based information on mind–body approaches and non-opioid pain strategies through its digest on nondrug approaches for pain, underscoring that, for many patients, the most sustainable relief comes from a combination of behavioral, physical, and, when necessary, pharmacologic tools rather than a single substance or intervention.

From a policy perspective, the central question is no longer whether kratom will remain part of the American landscape—it already is—but how it can be integrated, regulated, and studied in ways that maximize potential benefits while minimizing harm. Public health researchers are urging lawmakers to pair any consumer protection measures with investments in independent research and public education, so that patients, clinicians, and policymakers are not left making high-stakes decisions in an information vacuum. On the federal level, the FDA, CDC, and NIDA continue to track kratom trends and evaluate safety data, while in Congress, proposals such as a federal Kratom Consumer Protection Act have sparked debate about how to balance access and oversight.

For now, the story of kratom remains unfinished, a case study in how quickly a traditional plant medicine can be absorbed into a modern wellness economy and how slowly formal evidence and regulation can follow. For individuals considering kratom, the most prudent path may be one of cautious optimism: recognizing the plant’s real potential to ease suffering in specific contexts, while staying alert to its limitations, its risks, and the reality that no supplement, however promising, can substitute for comprehensive, evidence-based care when it comes to chronic pain, mental health, or addiction.